Findings from the BRIGHT trial published in JAMA

March 17, 2015

NEW YORK, NY - March 16, 2015 - Data from the BRIGHT trial published today in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Findings were first reported at last year's Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).

There has been recent controversy surrounding the optimal anticoagulant strategy for patients with AMI. Previous multicenter trials, such as HORIZONS-AMI and EUROMAX, have demonstrated superiority of bivalirudin to heparin plus glycoprotein IIb/IIIa inhibitors (GPI), but a recent single center trial, HEAT-PPCI, demonstrated the superiority of heparin monotherapy over bivalirudin alone, with concern for an increased rate of stent thrombosis observed in bivalirudin-treated patients. Due to these disparate results, the safety and efficacy of bivalirudin in patients with AMI undergoing PCI in contemporary practice is still controversial.

BRIGHT, a multicenter, open label trial was conducted with a 1:1:1 randomization that compared bivalirudin alone to heparin alone and heparin plus tirofiban in patients with AMI undergoing PCI. The trial randomized 2,194 patients with AMI eligible for emergency PCI from 82 Chinese sites to receive either bivalirudin with a post-PCI infusion (n=735), heparin alone (n=729), or heparin plus tirofiban with a post-PCI infusion (n=730).

The primary endpoint was 30-day net adverse clinical events (NACE), a composite of major adverse cardiac and cerebral events (MACCE; all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke) or any bleeding as defined by the Bleeding Academic Research Consortium (BARC) definition. The secondary endpoints were NACE at one year, as well as MACCE and bleeding at 30 days and one year.

After 30 days, NACE occurred in 65 (8.8%) bivalirudin-treated patients compared to 96 (13.2%) heparin-treated patients (relative risk [RR]: 0.67, 95%CI: 0.50-0.90; difference: -4.3%, 95%CI: -7.5% - -1.1%; P=0.008); and 124 (17.0%) heparin plus tirofiban-treated patients (RR for bivalirudin vs. heparin plus tirofiban: 0.52, 95%CI: 0.39-0.69; difference: -8.1%, 95%CI: -11.6% - -4.7%; P<0.001). Bleeding at 30 days was reduced by bivalirudin compared to heparin and heparin plus tirofiban (4.1% vs. 7.5% vs. 12.3% respectively, P<0.001).

There were no statistically significant differences between treatments in the 30-day rates of MACCE (5.0% vs. 5.8% vs. 4.9% respectively, P=0.74) and stent thrombosis (0.6% vs. 0.9% vs. 0.7% respectively, P=0.77), nor in acute (<24 hour) stent thrombosis (0.3% in each group).

At one year, bivalirudin resulted in sustained reductions in NACE compared to heparin (12.8% vs. 16.5%, RR: 0.78, 95%CI: 0.61-0.99; difference: -3.7%, 95%CI: -7.3% - -0.1%; p=0.048) and compared to heparin plus tirofiban (12.8% vs. 20.5%, RR: 0.62, 95%CI: 0.49-0.79; difference: -7.8%, 95%CI: -11.6% - -4.0%; p<0.001), due to lower rates of bleeding. Rates of MACCE and stent thrombosis at one year were not significantly different between the treatment groups.

"By reducing bleeding with comparable rates of MACCE and stent thrombosis, bivalirudin significantly improved overall 30-day and one year outcomes, compared with both heparin alone and heparin plus tirofiban in patients with AMI undergoing primary PCI," said Gregg W. Stone, MD, the study's senior author. Dr. Stone is Co-Director of CRF's Medical Research and Education Division. He is also Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center.
-end-
The BRIGHT trial was sponsored by the General Hospital of Shenyang Military Region, supported by a general research fund from the General Hospital of Shenyang Military Region, as well as nonprofit grants from the Chinese Government National Key R&D project for the 12th five-year plan (2011BAI11B07, 2012ZX093016-002), and a research grant and study drug supply from Salubris Pharmaceutical Co. (Shenzhen, China).

About CRF

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. For more information, visit http://www.crf.org.

Cardiovascular Research Foundation

Related Heparin Articles from Brightsurf:

UC San Diego researchers move closer to producing heparin in the lab
In a new study published in PNAS, UC San Diego researchers moved one step closer to the ability to make heparin in cultured cells.

Rivaroxaban superior to heparin in preventing blood clots after common orthopedic surgeries
The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Hitting HIT: Heparin therapy
Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT.

URI chemistry professor develops contaminant detection technique for heparin
In 2008, a contaminant eluded the quality safeguards in the pharmaceutical industry and infiltrated a large portion of the supply of the popular blood thinner heparin, sickening hundreds and killing about 100 in the US.

Synthetic version of popular anticoagulant poised for clinical trials
A synthetic version of low molecular weight heparin is poised for clinical trials and development as a drug for patients with clotting disorders, and those undergoing procedures such as kidney dialysis, heart bypass surgery, stent implantation, and knee and hip replacement.

Heparin stimulates food intake and body weight gain in mice
Research shows that heparin, which is well known for its role as an anticoagulant, can also promote food intake and body weight increase in animal models.

Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress.

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study today in JACC: Cardiovascular Interventions.

Smart patch releases blood thinners as needed
An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occurrence of dangerous blood clots.

Two differing medications used during heart procedure are both safe and effective, study finds
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study.

Read More: Heparin News and Heparin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.